www.alk.net
  • Patients
    • What is allergy
      • House dust mite allergy
      •  
      • Pollen allergy
      •  
      • Living with allergy
      •  
      • Socio-economic impact
      •  
    •  
    • What is allergic asthma
    •  
    • How is allergy diagnosed
    •  
    • Treating allergy
    •  
  •  
  • Healthcare Professionals
    • Treating allergy and asthma
    •  
    • Products
    •  
    • Adverse reactions
    •  
    • Initiation of treatment
    •  
    • Clinical trials
    •  
  •  
  • R&D
    • R&D pipeline
    •  
    • Understanding immunotherapy
    •  
    • Research
    •  
    • Congress activities
    •  
    • Clinical data sharing
    •  
  •  
  • Careers
    • Working at ALK
    •  
    • Vacant positions
    •  
  •  
  • Investors
    • Overview
    •  
    • Financial reporting
      • Risk management
      •  
      • Reporting standards
      •  
      • Auditors
      •  
    •  
    • Governance
      • IR policy
      •  
      • Management
      •  
      • Board of directors
      •  
      • Annual general meeting
      •  
      • Annual general meeting (DK)
      •  
    •  
    • News & Events
      • Company Releases
      •  
      • Company releases (DK)
      •  
      • Webcasts & presentations
      •  
      • Investor calendar
      •  
    •  
    • The Share
      • Dividend history
      •  
      • Analyst coverage
      •  
      • Analyst estimates
      •  
      • Shareholder information
      •  
      • Authorizations
      •  
      • ADR Programme
      •  
    •  
    • Contact IR
    •  
    • Management
    •  
    • Board of directors
    •  
    • AGM
    •  
    • AGM (DK)
    •  
    • Nyheder
    •  
    • Nyheder (EN)
    •  
  •  
  • Media
  •  
  • About
    • ALK at a glance
    •  
    • CSR
    •  
    • Production
    •  
    • Global presence
    •  
    • Organisation
    •  
    • History
    •  
    • Values
    •  
    • Owners
    •  
  •  
  • Select country
  •  
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar

« Back

Release date of annual report 2020 for ALK and audio cast

February 04, 2021

PDF Version

On Wednesday, 10 February 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its annual report for 2020.

ALK will host a meeting for analysts and institutional investors that day at 2.00pm (CET) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.

Participants in the conference call are kindly requested to call in before 1.55pm (CET). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the following participant pin code: 67633761#

ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

  • InvestorNews_04Feb21
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved